148 related articles for article (PubMed ID: 22517194)
1. MR, (18)F-FDG, and (18)F-AV45 PET correlate with AD PSEN1 original phenotype.
Saint-Aubert L; Payoux P; Hannequin D; Barbeau EJ; Campion D; Delisle MB; Tafani M; Viallard G; Péran P; Puel M; Chollet F; Demonet JF; Pariente J
Alzheimer Dis Assoc Disord; 2013; 27(1):91-4. PubMed ID: 22517194
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model.
Waldron AM; Wyffels L; Verhaeghe J; Richardson JC; Schmidt M; Stroobants S; Langlois X; Staelens S
J Alzheimers Dis; 2017; 55(4):1537-1548. PubMed ID: 27911309
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
Deleye S; Waldron AM; Verhaeghe J; Bottelbergs A; Wyffels L; Van Broeck B; Langlois X; Schmidt M; Stroobants S; Staelens S
J Nucl Med; 2017 Dec; 58(12):1977-1983. PubMed ID: 28611242
[TBL] [Abstract][Full Text] [Related]
4. In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice.
Waldron AM; Wintmolders C; Bottelbergs A; Kelley JB; Schmidt ME; Stroobants S; Langlois X; Staelens S
Alzheimers Res Ther; 2015 Dec; 7(1):76. PubMed ID: 26666747
[TBL] [Abstract][Full Text] [Related]
5. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.
Smith R; Wibom M; Olsson T; Hägerström D; Jögi J; Rabinovici GD; Hansson O
J Alzheimers Dis; 2016; 51(2):339-43. PubMed ID: 26836192
[TBL] [Abstract][Full Text] [Related]
6. Brain 18 F-Florbetapir PET/CT Findings in an Early-onset Alzheimer Disease Patient Carrying Presenilin-1 G378E Mutation.
Cistaro A; Quartuccio N; Cassalia L; Vai D; Guerra UP; Atzori C; Rainero I; Imperiale D
Alzheimer Dis Assoc Disord; 2022 Oct-Dec 01; 36(4):347-349. PubMed ID: 34132671
[TBL] [Abstract][Full Text] [Related]
7. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.
Villemagne VL; Ataka S; Mizuno T; Brooks WS; Wada Y; Kondo M; Jones G; Watanabe Y; Mulligan R; Nakagawa M; Miki T; Shimada H; O'Keefe GJ; Masters CL; Mori H; Rowe CC
Arch Neurol; 2009 Dec; 66(12):1537-44. PubMed ID: 20008660
[TBL] [Abstract][Full Text] [Related]
8. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
9. Presenilin-1 mutation is associated with a hippocampus defect in alzheimer's disease: Meta-Analysis for neuroimaging research.
Gu X; Zhao M; Han X; Liu L
Clin Neurol Neurosurg; 2020 Apr; 191():105679. PubMed ID: 32004985
[TBL] [Abstract][Full Text] [Related]
10. Probable Novel APP Met671Leu Mutation in a Chinese Han Family with Early-Onset Alzheimer's Disease.
Ma L; Wang F; Chen S; Wang S; Wang Z; Xia M; Li Y; Ma H; Shang J; Zhang J
Neuromolecular Med; 2024 Mar; 26(1):6. PubMed ID: 38504005
[TBL] [Abstract][Full Text] [Related]
11. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
12. In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions.
Klupp E; Förster S; Grimmer T; Tahmasian M; Yakushev I; Sorg C; Yousefi BH; Drzezga A
Brain Connect; 2014 Jun; 4(5):371-83. PubMed ID: 24870443
[TBL] [Abstract][Full Text] [Related]
13. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.
Schöll M; Almkvist O; Bogdanovic N; Wall A; Långström B; Viitanen M; Nordberg A
J Alzheimers Dis; 2011; 24(3):495-506. PubMed ID: 21297272
[TBL] [Abstract][Full Text] [Related]
14. Impact of MRI-based Segmentation Artifacts on Amyloid- and FDG-PET Quantitation.
Högenauer M; Brendel M; Delker A; Därr S; Weiss M; Bartenstein P; Rominger A; Alzheimer's Disease Neuroimaging Initiative
Curr Alzheimer Res; 2016; 13(5):597-607. PubMed ID: 27025775
[TBL] [Abstract][Full Text] [Related]
15. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
16. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
Schöll M; Wall A; Thordardottir S; Ferreira D; Bogdanovic N; Långström B; Almkvist O; Graff C; Nordberg A
Neurology; 2012 Jul; 79(3):229-36. PubMed ID: 22700814
[TBL] [Abstract][Full Text] [Related]
17. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.
Förster S; Grimmer T; Miederer I; Henriksen G; Yousefi BH; Graner P; Wester HJ; Förstl H; Kurz A; Dickerson BC; Bartenstein P; Drzezga A
Biol Psychiatry; 2012 May; 71(9):792-7. PubMed ID: 21679929
[TBL] [Abstract][Full Text] [Related]
18.
Ottoy J; Verhaeghe J; Niemantsverdriet E; De Roeck E; Wyffels L; Ceyssens S; Van Broeckhoven C; Engelborghs S; Stroobants S; Staelens S
Alzheimers Dement; 2019 Sep; 15(9):1172-1182. PubMed ID: 31405824
[TBL] [Abstract][Full Text] [Related]
19. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
Ng KP; Pascoal TA; Mathotaarachchi S; Chung CO; Benedet AL; Shin M; Kang MS; Li X; Ba M; Kandiah N; Rosa-Neto P; Gauthier S;
Neurology; 2017 May; 88(19):1814-1821. PubMed ID: 28404803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
